Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $32.58 Consensus Price Target from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned a consensus recommendation of “Buy” from the sixteen brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $32.5833.

A number of research firms have weighed in on DNLI. Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research report on Monday, November 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. JPMorgan Chase & Co. raised their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush cut their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th.

Denali Therapeutics Stock Down 1.0%

Shares of DNLI opened at $16.41 on Friday. The firm has a market cap of $2.41 billion, a P/E ratio of -5.64 and a beta of 1.11. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $24.34. The stock’s 50 day moving average is $17.28 and its two-hundred day moving average is $15.54. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.02. During the same period last year, the company earned ($0.63) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. Analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNLI. Hudson Bay Capital Management LP grew its holdings in shares of Denali Therapeutics by 5.2% during the third quarter. Hudson Bay Capital Management LP now owns 305,000 shares of the company’s stock worth $4,429,000 after buying an additional 15,000 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in Denali Therapeutics by 1.7% during the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after acquiring an additional 920 shares during the last quarter. Cantor Fitzgerald L. P. purchased a new stake in Denali Therapeutics during the 3rd quarter valued at about $653,000. CIBC Bancorp USA Inc. purchased a new stake in Denali Therapeutics during the 3rd quarter valued at about $205,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Denali Therapeutics in the 3rd quarter valued at about $667,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.